We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+57.48%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$514M
AUM Growth
-$7.79M
Cap. Flow
-$48M
Cap. Flow %
-9.34%
Top 10 Hldgs %
56.23%
Holding
206
New
96
Increased
32
Reduced
19
Closed
50

Top Buys

Rank Stock Value
1
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$11.2M
2
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$11.1M
3
ASXC
Asensus Surgical, Inc.
ASXC
+$8.33M
4
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$8.2M
5
WIMI
WiMi Hologram Cloud
WIMI
+$8.14M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$31.5M
2
AZN icon
AstraZeneca
AZN
+$18.2M
3
MRNA icon
Moderna
MRNA
+$12.1M
4
XWEL icon
XWELL
XWEL
+$6.41M
5
CVM icon
CEL-SCI Corp
CVM
+$3.62M

Sector Composition

Rank Sector Weight
1 Healthcare 13.44%
2 Technology 2.48%
3 Consumer Staples 2.16%
4 Communication Services 1.48%
5 Financials 0.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATNM icon
151
PUT
Actinium Pharmaceuticals
ATNM
$27M
$76K 0.01%
100
-281
-74% -$2.39K
PHIO icon
152
Phio Pharmaceuticals
PHIO
$11.5M
$62K 0.01%
+213
New +$70.8K
CSCI
153
CALL
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$53K 0.01%
+5
New +$554
PHAS
154
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$52K 0.01%
15,000
-50,000
-77% -$203K
KUST
155
CALL
Kustom Entertainment Inc
KUST
$696K
– –
0
– –
RDGT
156
Ridgetech Inc
RDGT
$836K
$28K 0.01%
1
– –
AMBO
157
Ambow Education Holding
AMBO
$6.12M
– –
-15,177
Closed -$329K
ASTC icon
158
Astrotech Corp
ASTC
$12.3M
– –
-21,143
Closed -$1.12M
ATHE
159
Alterity Therapeutics
ATHE
$82.8M
– –
-18,584
Closed -$249K
ATNM icon
160
CALL
Actinium Pharmaceuticals
ATNM
$27M
– –
-1,308
Closed -$1.02M
ATXS
161
DELISTED
Astria Therapeutics
ATXS
– –
-18,004
Closed -$231K
AUPH icon
162
PUT
Aurinia Pharmaceuticals
AUPH
$1.92B
– –
-757
Closed -$1.05M
AZN icon
163
AstraZeneca
AZN
$270B
– –
-182,500
Closed -$18.2M
AZN icon
164
PUT
AstraZeneca
AZN
$270B
– –
-1,746
Closed -$17.5M
BIIB icon
165
Biogen
BIIB
$31.8B
– –
-116,970
Closed -$31.5M
CRMD icon
166
CALL
CorMedix
CRMD
$566M
– –
-839
Closed -$623K
CRMD icon
167
PUT
CorMedix
CRMD
$566M
– –
-894
Closed -$664K
CTRM icon
168
Castor Maritime
CTRM
$18M
– –
-28,506
Closed -$527K
CVM icon
169
CEL-SCI Corp
CVM
$20.4M
– –
-10,339
Closed -$3.62M
EFOI icon
170
PUT
Energy Focus
EFOI
$18M
– –
-17
Closed -$48K
EVOK
171
DELISTED
Evoke Pharma
EVOK
– –
-451
Closed -$168K
EVOK
172
PUT
DELISTED
Evoke Pharma
EVOK
– –
-8
Closed -$289K
GLBS icon
173
Globus Maritime Ltd
GLBS
$63M
– –
-290,535
Closed -$1.66M
GOVX icon
174
GeoVax Labs
GOVX
$3.74M
– –
-150
Closed -$191K
GOVXW
175
DELISTED
GeoVax Labs Warrants
GOVXW
– –
-275,695
Closed -$283K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2021 Portfolio in Review

As of Q1 2021, Sabby Management held 206 positions worth $514M, down 1.5% from $522M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sabby Management withdrew a net $48M in Q1 2021, closing 50 positions and reducing 19 holdings. Its most notable exit was Biogen, an estimated $31.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, down from 18% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Sorrento Therapeutics, Inc. worth $8.81M.

  • Sabby Management's largest Q1 2021 buy was Sorrento Therapeutics, Inc.: 1,064,933 shares worth $8.81M.
  • Sabby Management added most to Odonate Therapeutics, Inc. Common Stock in Q1 2021, an estimated $11.1M increase.
  • Sabby Management's biggest Q1 2021 reduction was AVEO Pharmaceuticals, Inc., cutting an estimated $494K.
  • Sabby Management fully exited Biogen in Q1 2021, selling an estimated $31.5M.
  • Sabby Management's ten largest holdings make up 56% of its $514M portfolio in Q1 2021.
  • Sabby Management opened 96 new positions and closed 50 in Q1 2021.
  • Sabby Management's portfolio value fell 1.5% quarter-over-quarter to $514M.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.